Tivic Health Transforms into Immunotherapy Company

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 5 days ago

0mins

TIVC+2.24%

Should l Buy TIVC?

Source: seekingalpha

Strategic Transformation: Under CEO Michael Handley's leadership, Tivic Health has fully pivoted to immunotherapy, focusing on the TLR5 platform with candidates like Entolimod and Entolasta, targeting the oncology supportive care market projected to grow from $15 billion to $20 billion.
In-House Manufacturing: The company has completed its acquisition of in-house manufacturing capabilities and launched Velocity Bioworks, which is expected to provide cost efficiencies and a new revenue stream, significantly reducing development timelines and costs for Entolimod while enhancing supply chain control.
Improved Financial Position: As of December 31, 2025, Tivic's cash and cash equivalents totaled $12.6 million, a substantial increase from $2 million in 2024, indicating improved financial health following new business lines and acquisitions.
Market Opportunities: Tivic is actively engaging with U.S. government agencies for potential biodefense contracts and plans to initiate clinical trials for Entolimod within the year, showcasing the company's strong potential and readiness in the biotherapeutics market.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy TIVC?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on TIVC

About TIVC

Tivic Health Systems, Inc. is a late-stage therapeutics company. The Company’s biopharma program is focused on advancing its drug product candidate, Entolimod, into manufacturing, conducting process validation utilizing the output of such manufacturing with the intent of selling the biologic compounds either inside or outside the United States. The Company’s bioelectronic program is focused on developing non-invasive medical devices that influence biologic functions associated with various diseases and conditions. It has an over-the-counter device, ClearUP, that treats sinus pain and pressure. The Company’s Toll-like Receptor 5 (TLR5) program’s lead product candidate is the late-stage TLR5 agonist, Entolimod, to treat acute radiation syndrome (ARS) and for remediating side effects of medical radiation and chemotherapy. The Company offers contract development and manufacturing organization through its subsidiary Velocity Bioworks, Inc.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Tivic Health Systems Reports FY 2025 Financial Overview

5 days agoseekingalpha

Rising Operating Expenses: Tivic Health's operating expenses for FY 2025 are projected to reach $7.9 million, significantly up from $4.5 million in 2024, indicating ongoing investments in business expansion and R&D that may pressure short-term profitability.
Increased Net Loss: The expected net loss for 2025 is between $8.8 million and $9.1 million, compared to $5.7 million in 2024, raising concerns among investors regarding the company's financial health, which could negatively impact stock performance.
Improved Cash Position: The company anticipates cash and working capital of $12.6 million and $12.4 million in 2025, a substantial increase from $2.0 million in 2024, reflecting positive progress in cash management and liquidity that supports future operations and investments.
Market Opportunity Outlook: Following its strategic transformation, Tivic Health has identified a $20 billion oncology market opportunity, indicating potential for expansion into new market segments that could lay the groundwork for future growth.